Research programme: antibody therapeutics - Agenus/Human Genome Sciences
Latest Information Update: 23 Mar 2018
At a glance
- Originator 4-Antibody; Human Genome Sciences
- Developer Agenus; Human Genome Sciences
- Class Antibodies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 16 Mar 2018 Agenus has issued and pending patents for Retrocyte Display™ technology platform in USA
- 16 Jul 2016 No recent reports of development identified for research development in Undefined in Switzerland (Parenteral)
- 16 Jul 2016 No recent reports of development identified for research development in Undefined in USA (Parenteral)